The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000579392
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
20/04/2026
Date registered
Help: Date registered
8/05/2026
Date last updated
Help: Date last updated
8/05/2026
Date data sharing statement initially provided
Help: Data sharing statement date
8/05/2026
Type of registration
Help: Type of registration
Retrospectively registered

Titles & IDs
Public title
Cystoscopic Local Endoscopic Application of RADA16 (PuraStat®) for refractory haematuria secondary to Radiation Cystitis) (CLEAR-RC)
Scientific title
Cystoscopic Local Endoscopic Application of RADA16 (PuraStat®) for refractory haematuria secondary to Radiation Cystitis in adults) (CLEAR-RC)
Additional trial identifiers [1] 317161 0
Nil
Universal Trial Number (UTN)
Trial acronym
CLEAR-RC
Related trial records

Health condition
Health condition(s) studied:
radiation cystitis 341600 0
Haematuria 341601 0
Condition category
Condition code
Surgery 337677 337677 0 0
Surgical techniques
Renal and Urogenital 337816 337816 0 0
Other renal and urogenital disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
- A urologist will apply RADA16 (Purastat- 3 or 5 ml depending on the extent of the radiation cystitis) via a cystoscopy under general or local anaesthetic. This is applied during the surgery (cystoscopy). It is done as a day procedure in a hospital. The patient will be discharged the same day
- RADA 16 (Purastat) is a gel which is licensed for haemostasis and has been used effectively to treat radiation proctitis and there have been limited case series on its in radiation cystitis
- The procedure takes about 30 mins to perform

- The frequency will be dictated by the response to treatment- some people will only have one application, some people may have multiple applications if they still bleed from radiation cystitis. There is no limit to the number of applications for this study.
- Urologists in this trial will not need any special training to perform this procedure as it is straightforward and within their usual scope of practice

- Audit of operation procedures will be used to monitor adherence to intervention
Intervention code [1] 333833 0
Treatment: Devices
Intervention code [2] 333932 0
Treatment: Surgery
Description of the comparator or control
No control
Control group
Uncontrolled

Outcomes
Primary outcome [1] 345154 0
Efficacy of RADA16 for treating clinically significant haematuria secondary to radiation cystitis.
Timepoint [1] 345154 0
6 weeks post RADA-16 application
Primary outcome [2] 345345 0
Safety of RADA16 for treating clinically significant haematuria secondary to radiation cystitis.
Timepoint [2] 345345 0
Within 3 months of RADA16 application
Secondary outcome [1] 460698 0
To determine if RADA16 changes the cystoscopic appearance of radiation cystitis changes
Timepoint [1] 460698 0
3 months post RADA16 application

Eligibility
Key inclusion criteria
- Patients 18 years and over old
- Background of abdominopelvic radiotherapy
- Clinically significant haematuria secondary to known or suspected radiation cystitis (confirmed during study if not previously).



“Clinically significant haematuria” = ANY of the below criteria

Resulting in previous or current hospital admission/presentations AND/OR

Anaemia* AND/OR

Requiring previous or ongoing blood transfusion AND/OR

Intravesical clot formation AND/OR

Previously or currently requiring intervention including but not limited to: hospital admission, in-dwelling catheterisation, continuous bladder irrigation, bladder washouts, surgical, interventional radiology or cystoscopic intervention with or without cystodiathermy, intravesical instillations or irrigation such as alum, ilauril, or formalin, blood transfusions AND/OR

Severe enough to cause symptoms for the patient** AND/OR

Recurrent macro haematuria prompting the patient to seek Urology review and management

*Anaemia in this setting is defined as:

- An acute drop in haemoglobin by at least 10 g/l, associated with haematuria OR

- Chronic if Hb < 130 g/l (according to normal reference ranges provided by WHO for men; 110-129 g/l -mild anaemia, 80-109 g/l moderate, <80 g/l severe) OR

- Ongoing/active bleeding which does not satisfy these two criteria, but the clinician is concerned about the severity of bleeding will ultimately result in anaemia over time.

** Symptoms of EITHER:

- symptomatic anaemia with fatigue/lethargy, shortness of breath on exertion or chest pain, OR

- lower urinary tract symptoms expected to be secondary to clots, such as sensation of incomplete emptying, urinary frequency, urinary retention

Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Alternative diagnosis to radiation cystitis found at time of cystoscopy (e.g. bladder tumour)

Patients with acute concurrent urosepsis – can be recruited after resolution

Patients deemed too high risk or unwell to facilitate intervention

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
ACT,NSW,QLD,SA,WA,VIC

Funding & Sponsors
Funding source category [1] 321665 0
Hospital
Name [1] 321665 0
Nepean Public Hospital
Country [1] 321665 0
Australia
Funding source category [2] 321746 0
University
Name [2] 321746 0
University of Sydney
Country [2] 321746 0
Australia
Funding source category [3] 321747 0
Hospital
Name [3] 321747 0
Sydney Adventist Hospital
Country [3] 321747 0
Australia
Primary sponsor type
University
Name
Sydney Unversity
Address
Country
Australia
Secondary sponsor category [1] 324489 0
None
Name [1] 324489 0
Address [1] 324489 0
Country [1] 324489 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320198 0
Nepean Blue Mountains Local Health District
Ethics committee address [1] 320198 0
Ethics committee country [1] 320198 0
Australia
Date submitted for ethics approval [1] 320198 0
01/07/2025
Approval date [1] 320198 0
19/08/2025
Ethics approval number [1] 320198 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149738 0
Dr Jonathan Kam
Address 149738 0
Nepean Hospital, Derby St, Kingswood, NSW, Australia 2747
Country 149738 0
Australia
Phone 149738 0
+61 02 9052 7586
Fax 149738 0
Email 149738 0
Contact person for public queries
Name 149739 0
Jonathan Kam
Address 149739 0
Nepean Hospital, Derby St, Kingswood, NSW, Australia 2747
Country 149739 0
Australia
Phone 149739 0
+61 02 9052 7586
Fax 149739 0
Email 149739 0
Contact person for scientific queries
Name 149740 0
Jonathan Kam
Address 149740 0
Nepean Hospital, Derby St, Kingswood, NSW, Australia 2747
Country 149740 0
Australia
Phone 149740 0
+61 02 9052 7586
Fax 149740 0
Email 149740 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.